Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors
2025-522559-25-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Sep 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of culture-expanded adipose-derived regenerative cells in xerostomia, hyposalivation and head and neck cancer (HNC) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Unstimulated whole salivary flow rate at 8 months. Planned start Sep 2025; status: authorised.
02
Drugs
culture-expanded adipose-derived regenerative cells
03
Conditions
xerostomiahyposalivationhead and neck cancer (HNC)
Beyond the preview
Go deeper on 2025-522559-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522559-25-00.